Predictive
Oncology (NASDAQ: POAI) is assisting clinicians and researchers in
improving outcomes for cancer patients via its AI-driven, tumor-profiling
platform. A recent article discussing the company reads, “POAI’s technology
combines its database of evidence documenting actual drug responses of cancer
patients’ tumors with artificial intelligence (AI) to create an invaluable
predictive tool for clinicians and researchers. Predictive Oncology’s data
offers a valuable, customizable assessment method that can be used by
oncologists to determine the best drug for fighting a specific patient’s
cancer. This disruptive technology is the first of its kind and is also meeting
a critical need in the pharmaceutical, diagnostic and biotech industries to
speed up the search for new precision therapies by providing tools to better
predict how new drugs work on different cancers (http://ibn.fm/0YnNI). . . . POAI’s wholly owned
subsidiaries — Helomics and TumorGenesis — are working together to bring these
important precision-medicine tools to physicians.”
To view the full article, visit http://ibn.fm/7xJbm
About Predictive Oncology Inc.
Predictive Oncology (formerly Precision Therapeutics Inc.)
operates through its three business units: Helomics, TumorGenesis and Skyline
Medical. Helomics applies artificial intelligence to rich data gathered from
patient tumors to both personalize cancer therapies for patients and drive the
development of new targeted therapies in collaborations with pharmaceutical
companies. Helomics’ CLIA-certified lab provides clinical testing that assists
oncologists in individualizing patient-treatment decisions by providing an
evidence-based road map for therapy. In addition to its proprietary
precision-oncology platform, Helomics offers boutique CRO services that
leverage its TruTumor, patient-derived tumor models coupled to a wide range of
multi-omics assays (genomics, proteomics and biochemical), and an AI-powered
proprietary bioinformatics platform (D-CHIP) to provide a tailored solution to
its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is
developing a new rapid approach to growing tumors in the laboratory, which
essentially “fools” cancer cells into thinking they are still growing inside a
patient. Its proprietary Oncology Discovery Technology Platform kits will
assist researchers and clinicians to identify which cancer cells bind to
specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’
Oncology Capture Technology Platforms, which isolate and help categorize an
individual patient’s heterogeneous tumor samples to enable the development of
patient-specific treatment options. Helomics and TumorGenesis are focused on
ovarian cancer. Predictive Oncology’s Skyline Medical division markets its
patented and FDA-cleared STREAMWAY System, which automates the collection,
measurement and disposal of waste fluid, including blood, irrigation fluid and
others, within a medical facility, through both domestic and international
divisions. The company has achieved sales in five of the seven continents
through both direct sales and distributor partners. For more information, visit
the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
